FIELD: medicine.
SUBSTANCE: present invention provides a combination comprising at least oncolytic virus and one or more immunological control point modulators for use in treating a proliferative disease, such as cancer. It also refers to a kit containing said oncolytic virus and said one or more immunological control point modulators in separate containers. It also refers to a pharmaceutical composition containing an effective amount of said oncolytic virus and said one or more immunological control point modulators.
EFFECT: disclosed is a combination of oncolytic virus with modulators of immunological control points.
21 cl, 7 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2508401C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2503717C2 |
| POX VIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2557312C2 |
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT | 2019 |
|
RU2794261C2 |
| ANTICANCER COMPOSITION CONTAINING TUMOR-SPECIFIC ONCOLYTIC ADENO VIRUS AND INHIBITOR OF CONTROL POINT OF IMMUNE RESPONSE | 2018 |
|
RU2777523C2 |
| ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR | 2018 |
|
RU2740713C1 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
